Navigation Links
Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer
Date:10/1/2013

THOUSAND OAKS, Calif., Oct. 1, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) for $125 per share in cash. As announced on Aug. 25, the purchase price is $9.7 billion net of estimated Onyx cash. The tender offer expired at 12:00 midnight New York City time on Oct. 1, 2013. Amgen expects to complete the acquisition of Onyx later today through a merger under Section 251(h) of the General Corporation Law of the State of Delaware.

"Amgen's acquisition of Onyx fits perfectly with our commitment to advancing medicines for cancer patients around the world," said Robert A. Bradway, chairman and chief executive officer of Amgen.  "We look forward to working together with the talented staff at Onyx to make the most of our exciting oncology portfolio and pipeline."

As of the expiration of the tender offer, approximately 57,698,132 shares were validly tendered and not withdrawn in the tender offer, representing approximately 78.5 percent of Onyx's outstanding shares, according to the depositary for the tender offer. The condition to the tender offer that a majority of Onyx's outstanding shares on a fully-diluted basis be validly tendered and not withdrawn has been satisfied. As a result, Amgen has accepted for payment and will promptly pay for all validly tendered shares.

As a result of the merger planned to be effected later today, all remaining eligible Onyx shares will be converted into the right to receive $125 per share in cash, without interest and less any applicable withholding taxes,
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amgen and Onyx Pharmaceuticals Announce Early Termination of HSR Waiting Period for Amgens Acquisition of Onyx
2. Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil
3. Amgen To Participate At Citis 8th Annual Biotech Conference
4. Healthcare Briefing - Leading Medical Companies in the News: Bio-Solutions, Catalyst Pharmaceutical, MannKind, Amgen, Accuray
5. Amgen to Highlight New Data at Upcoming ESC Congress 2013
6. Acquisition of Onyx Pharmaceuticals, Inc. by Amgen Inc. May Not Be in the Best Interests of Onyx Pharmaceuticals, Inc. Shareholders
7. Amgen To Acquire Onyx Pharmaceuticals For $125 Per Share In Cash
8. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
9. Amgens Second Quarter 2013 Revenues Increased 5 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 3 Percent To $1.89
10. Amgen Announces Webcast of 2013 Second Quarter Financial Results
11. Amgen Award For Science Teaching Excellence Honors Outstanding Teachers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... China , Jan. 23, 2015 Tianyin Pharmaceutical ... company that specializes in the development and sale of ... generics and active pharmaceutical ingredients (API) today announced the ... (JCM) API operation. 1. Following the September ...
(Date:1/22/2015)... RMD ) today announced results for its quarter ... million, a 10 percent increase compared to the quarter ended ... currency basis). Net income was $91.2 million, an increase of ... Diluted earnings per share for the quarter were $0.64, an ...
(Date:1/22/2015)... , Jan. 22, 2015  Profil Institute for Clinical Research, ... and obesity, announced today a new textbook,  Translational Research ... by Springer, a leading global scientific publisher. ... illustrate techniques for use in early phase clinical studies ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3
... BRISBANE, Australia, Feb. 13 Progen,Pharmaceuticals Limited ... efficacy results from a phase 2 investigator-initiated ... agent Taxotere(R),(docetaxel) administered to patients with prostate ... Sydney Haematology and Oncology Clinics, the,principal investigator ...
... demonstrates,for the first time that embryonic stem cells can ... finding which is an important step,in the utilization of ... bone marrow transplantation. This hopeful news for patients with,severe ... was prepublished online in Blood, the official journal of ...
Cached Medicine Technology:Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium 2Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium 3A Functional Immune System Can Be Derived From Embryonic Stem Cells, Preliminary Study Finds 2A Functional Immune System Can Be Derived From Embryonic Stem Cells, Preliminary Study Finds 3
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering ... follow it on Facebook, Twitter, and Pinterest. The fans will ... draws a lottery every week. , Moreover, the company has ... Click Angelweddingdress homepage for more information. , ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A new ... of experience and person-centeredness in the long-term care environment ... action across the continuum. The paper, “The Power of ... engages perspectives and practices of the patient, resident and ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Joan Lunden, ... keynote speaker at the upcoming 32nd Annual Miami ... Physicians’ Education Resource®, LLC (PER®) , shares that ... have gone undetected if she had not followed up ...
(Date:1/22/2015)... Four years since the release of their debut recording Love ... of Avasa & Matthew Love – the duo are pleased to ... through White Swan Records on February 24, 2015. , THE ROAD ... available to all of us to walk out of the mire ...
(Date:1/22/2015)... has released a new blog post presenting a list of vehicles ... , Some types of vehicles cannot be covered under an ... post to see if their vehicle qualifies for auto insurance coverage. ... the cars that cannot be covered by a plan. Clients have ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... connect with schools and education information. , ... ... pursuing medical assisting degrees, choosing the right school just got ... website ( http://www.mymedicalassistingdegree.com/ ), students can learn about medical assistant ...
... monitoring means type 1 patients can avoid retinopathy, study ... good control over one,s blood sugar levels can help ... serious disorder that damages the eye,s retina, researchers say. ... that confirms prior large studies. The findings were published ...
... 2008 Thousands of the world,s top scientists and ... present their latest research at the 58th Annual Meeting ... Philadelphia, Pennsylvania on November 11-15, 2008. , A ... Meeting will provide information about important new research findings ...
... meat and processed meats, researchers say , , FRIDAY, Nov. 14 ... such as red and processed meats -- may be a ... the conclusion of a U.S. National Cancer Institute study that ... about their eating habits over eight years. , Previous research ...
... journal published by The Feinstein Institute for ... functioning and disease pathogenesis at the molecular ... to use that knowledge in the design ... treatment, prognosis, and prevention. Featured in ...
... and athletic enhancer, sales of acai products have dramatically increased in the ... from acai palms that may reach heights in excess of 60 feet ... palm. , ... Green Bay, WI (PRWEB) November 14, 2008 -- Though ...
Cached Medicine News:Health News:MyMedicalAssistingDegree.com Provides School-Search Help for Students 2Health News:Genetic disease treatments and pharmacogenetics: From scientific discovery to medical delivery 2Health News:Genetic disease treatments and pharmacogenetics: From scientific discovery to medical delivery 3Health News:Genetic disease treatments and pharmacogenetics: From scientific discovery to medical delivery 4Health News:Genetic disease treatments and pharmacogenetics: From scientific discovery to medical delivery 5Health News:Genetic disease treatments and pharmacogenetics: From scientific discovery to medical delivery 6Health News:Genetic disease treatments and pharmacogenetics: From scientific discovery to medical delivery 7Health News:Genetic disease treatments and pharmacogenetics: From scientific discovery to medical delivery 8Health News:Saturated Fats Linked to Cancer of Small Intestine 2Health News:Researchers Tackle CLL, Diabetes and Trauma-Hemorrhage, 2Health News:Research Finds The Brazilian Acai Absorbs Much Better Than Any Other Fruit 2
The KAVD Venous Cannula is the first of its kind. It is a combination of cannulae/venous line designed to "bridge the gap between the patient and the Medtronic Resting Heart System circuit....
... Pediatric Arterial Cannula is second ... of pediatric arterial cannulae. It ... models such as a kink-resistant, ... Flow-Guard™ introducer technology for easy ...
The Select 3D Arterial cannulae from Medtronic features a tip configuration which diffuses the flow through multiple outlets. This unique tip design provides reduced velocity with one central and thr...
The Select Series® Arterial Cannulae utilize a state-of-the-art dip-molding technology. This process allows molding of a one-piece, wire-wound cannula that is flexible and kink-resistant....
Medicine Products: